- Monte Rosa Therapeutics presented **preclinical data** for MRT-6160, a VAV1-directed molecular glue degrader, at ACR Convergence 2025.  **[1826457_df0e54aa61fe4a09865b11b9faad67b3_0]** 
- The data showed MRT-6160 **inhibited disease pathology** and attenuated T and B cell effector functions in a spontaneous autoimmune disease mouse model, indicating its potential to treat multiple rheumatic autoimmune and inflammatory diseases, including Sjögren’s disease, systemic lupus erythematosus, and rheumatoid arthritis.  **[1826457_df0e54aa61fe4a09865b11b9faad67b3_0]** **[1826457_df0e54aa61fe4a09865b11b9faad67b3_1]** 
- MRT-6160 is being advanced towards **Phase 2 studies** under an agreement where Novartis holds exclusive worldwide rights to develop, manufacture, and commercialize the drug.  **[1826457_df0e54aa61fe4a09865b11b9faad67b3_0]** **[1826457_df0e54aa61fe4a09865b11b9faad67b3_2]** 
- Monte Rosa is eligible to receive up to **$2.1 billion** in development, regulatory, and sales milestones, will co-fund Phase 3 clinical development, share U.S. profits and losses, and receive tiered royalties on ex-U.S. net sales.  **[1826457_df0e54aa61fe4a09865b11b9faad67b3_2]**

Monte Rosa Therapeutics Presents Preclinical Data for MRT-6160 and Details Novartis Partnership

- Monte Rosa Therapeutics announced a **new collaboration with Novartis**, receiving **$120 million upfront** for an undisclosed preclinical portfolio, which is expected to **extend the company's cash runway**.  **[1826457_2144240_0]** **[1826457_2144240_5]** 
- The lead I&I asset, **MRT-6160 (VEF1 degrader)**, is in Phase 1, with preclinical studies showing **no toxicities** and Phase 1 data demonstrating **no safety concerns** and **complete VEF1 degradation**.  **[1826457_2144240_2]** 
- The company is advancing its **Next7 program** through a Phase 1 study, targeting the NLRP3 inflammasome pathway with the goal of achieving **60% plus inhibition of CRP**.  **[1826457_2144240_3]** **[1826457_2144240_4]** 
- In oncology, the **MRT-2359 GSPT1 degrader** showed encouraging early data in **three prostate cancer patients** (one partial response, two stable diseases) in March 2025, and the company plans to release data from an expanded cohort of **20 to 30 patients by year-end**.  **[1826457_2144240_5]** 
- Monte Rosa reported **just below $300 million in cash** in Q2 2025, with previous runway guidance **into 2028**.  **[1826457_2144240_5]**

Monte Rosa Therapeutics (GLUE)